Publication: Soluble CD30 serum level - an adequate marker for allograft rejection of solid organs?
Loading...
Date
2007
Authors
Schlaf, G. ; Altermann, W.W. ; Rothhoff, A. ; Seliger, B.
item.page.secondaryauthor
item.page.director
Publisher
Murcia : F. Hernández
publication.page.editor
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
The CD30 molecule, a 120 kDa cell surface
glycoprotein, is a member of the tumor necrosis factor
receptor (TNF-R) superfamily and was originally
identified on the surface of Reed-Sternberg cells and
anaplastic large cell lymphomas in Hodgkin’s disease
patients. In addition to lymphoproliferative disorders the
expression of CD30 was found in both activated CD8+
and CD4+ Th2 cells which lead to the activation of Bcells
and consequently to the inhibition of the Th1-type
cellular immunity. The membrane-bound CD30
molecule can be proteolytically cleaved, thereby
generating a soluble form (sCD30) of about 85 kDa.
Low serum levels of soluble CD30 were found in
healthy humans, whereas increased sCD30 serum
concentrations were detected under pathophysiological
situations such as systemic lupus erythematosus,
rheumatoid arthritis, certain viral infections and adult T
cell leukaemia/lymphoma. In addition, it has recently
been suggested that pre- or post-transplant levels of
sCD30 represent a biomarker for graft rejection
associated with an impaired outcome for transplanted
patients. We here review (i) the current knowledge of the
clinical significance of sCD30 serum levels for solid
organ transplantations and (ii) our own novel data
regarding inter- and intra-individual variations as well as
time-dependent alterations of sCD30 levels in patients. (iii) Based on this information the implementation of
sCD30 as predictive pre-transplant or post-transplant
parameter for solid organ transplantation is critically
discussed.
publication.page.subject
Citation
item.page.embargo
Ir a Estadísticas
Sin licencia Creative Commons.